Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at $3,671,117.80. This represents a 1.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded up $0.89 during midday trading on Friday, reaching $92.22. 3,381,397 shares of the company were exchanged, compared to its average volume of 4,354,287. The stock’s 50-day moving average price is $86.73 and its 200-day moving average price is $83.87. The stock has a market cap of $53.10 billion, a P/E ratio of 49.05, a PEG ratio of 2.29 and a beta of 0.86. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the prior year, the company earned $0.64 EPS. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on EW. Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research report on Tuesday, June 16th. Barclays restated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Evercore reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Finally, TD Cowen reiterated a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $97.09.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of EW. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $266,000. NewEdge Advisors LLC increased its stake in shares of Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares during the period. Sei Investments Co. lifted its stake in shares of Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after acquiring an additional 58,988 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after acquiring an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina boosted its holdings in Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after acquiring an additional 1,065 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.